Hematologic aspects of systemic lupus erythematosus. Current concepts

Area of Science:

• Hematology
• Immunology
• Rheumatology

Background:

• Systemic lupus erythematosus (SLE) is an autoimmune disease affecting multiple organ systems.
• Hematopoietic abnormalities are common in SLE, impacting red blood cells, white blood cells, and platelets.
• Understanding these hematologic manifestations is crucial for managing SLE patients.

Purpose of the Study:

• To review the spectrum of hematopoietic abnormalities in systemic lupus erythematosus.
• To discuss the underlying mechanisms and clinical significance of these hematologic changes.
• To outline current therapeutic strategies for managing these complications.

Main Methods:

• Review of existing literature on hematologic manifestations in SLE.
• Analysis of the pathophysiology of anemia, leukopenia, and thrombocytopenia in SLE.
• Evaluation of treatment outcomes for corticosteroid therapy, splenectomy, and immunosuppressive agents.

Main Results:

• Anemia affects over 50% of SLE patients, often linked to chronic disease.
• Hemolysis occurs in about 10% of patients with a positive Coombs' test.
• Leukopenia and thrombocytopenia are common, frequently driven by autoantibodies and increased peripheral destruction, respectively.

Conclusions:

• Hematopoietic abnormalities are integral to the clinical presentation of SLE.
• Corticosteroids are effective in managing most hematologic issues, but splenectomy or immunosuppression may be needed for refractory cases.
• Further research into the immunopathogenesis of these disorders can lead to improved targeted therapies.